OKYO Pharma
OKYO
10 hedge funds and large institutions have $1.15M invested in OKYO Pharma in 2025 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 2 closing their positions.
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
25% more funds holding
Funds holding: 8 → 10 (+2)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
5.07% less ownership
Funds ownership: 6.84% → 1.77% (-5.1%)
78% less capital invested
Capital invested by funds: $5.14M → $1.15M (-$3.99M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$210K |
| 2 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$38.2K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$4.71K |
| 4 |
Morgan Stanley
New York
|
+$22 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DIG
Dauntless Investment Group
Etna,
New Hampshire
|
-$4.23M |
| 2 |
Northern Trust
Chicago,
Illinois
|
-$114K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$30.7K |
OKYO Hedge Fund Activity: Q4 2025 in Review
10 of the 8,281 institutional investors tracked by Wall St. Rank reported a position in OKYO Pharma (OKYO) for Q4 2025, worth a combined $1.15M — down 78% from $5.14M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new OKYO positions and 2 closed out — a net gain of 2 holders — while 1 added to existing stakes and 1 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $210K. The largest seller was Dauntless Investment Group, cutting an estimated $4.23M.
- 10 institutional investors held OKYO Pharma (OKYO) as of Q4 2025, up from 8 in Q3 2025.
- Funds reported $1.15M of OKYO Pharma stock for Q4 2025, down 78% quarter-over-quarter.
- 4 funds opened new OKYO Pharma positions in Q4 2025 and 2 closed out, a net change of +2 holders.
- The largest OKYO Pharma buyer in Q4 2025 was Renaissance Technologies, an estimated $210K added.
- The largest OKYO Pharma seller in Q4 2025 was Dauntless Investment Group, an estimated $4.23M sold.
Based on aggregated 13F filings for Q4 2025.